<DOC>
	<DOC>NCT00616980</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of intramuscular injections of adult stem cells in patients with Critical Limb Ischemia (CLI).</brief_summary>
	<brief_title>Injection of Autologous CD34-Positive Cells for Critical Limb Ischemia</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>2180 years of age moderate or highrisk Critical Limb Ischemia (Rutherford Clinical Severity Score 4 or 5) unsuitable for conventional revascularization advanced CLI (Rutherford Clinical Severity Score 6) characterized by extensive tissue loss or gangrene advance AV block or NYHA Class III or Class IV heart failure myocardial infarction within 3 months of treatment successful coronary or lower extremity revascularization within 3 months of study enrollment arterial insufficiency in the lower extremity is the result of a nonatherosclerotic disorder with the exception of thromboangitis obliterans (Buerger's Disease) comorbidity associated with life expectancy of less than 1 year</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>PAD</keyword>
	<keyword>PVD</keyword>
	<keyword>CLI</keyword>
	<keyword>Stem Cells</keyword>
</DOC>